Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AMROI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2023124537A1+ADC2
|
|||||
| Synonyms |
WO2023124537A1+ADC2
Click to Show/Hide
|
|||||
| Organization |
JENKEM TECHNOLOGY CO., LTD. (LIAONING)
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR mAb
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
DBCO-VC-PAB
|
Linker Info | ||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.126 nM | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Cells were cultured in a 5% CO2 cell incubator at 37°C for 24 hours. Cytotoxicity test contains about 10000 cells when 101uL is added to each well.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||